ML
REGN icon

McAdam LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

McAdam LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-517
Closed -$399K – 466
2025
Q4 		$399K Buy
+517
New +$351K 0.02% 275
2025
Q1 		– Sell
-2,643
Closed -$1.88M – 380
2024
Q4 		$1.88M Sell
2,643
-1
-0% -$839 0.1% 103
2024
Q3 		$2.78M Sell
2,644
-19
-0.7% -$21.1K 0.16% 78
2024
Q2 		$2.8M Sell
2,663
-26
-1% -$25.2K 0.17% 71
2024
Q1 		$2.59M Buy
2,689
+4
+0.1% +$3.8K 0.17% 73
2023
Q4 		$2.36M Sell
2,685
-8
-0.3% -$6.59K 0.17% 73
2023
Q3 		$2.22M Buy
2,693
+9
+0.3% +$7.07K 0.18% 69
2023
Q2 		$1.93M Buy
2,684
+17
+0.6% +$13.1K 0.16% 79
2023
Q1 		$2.19M Sell
2,667
-94
-3% -$70.9K 0.2% 74
2022
Q4 		$1.74M Buy
2,761
+86
+3% +$63.5K 0.17% 62
2022
Q3 		$1.84M Buy
2,675
+1
+0% +$629 0.2% 74
2022
Q2 		$1.58M Sell
2,674
-88
-3% -$57.2K 0.17% 80
2022
Q1 		$1.93M Buy
2,762
+1
+0% +$633 0.18% 66
2021
Q4 		$1.74M Buy
2,761
+1
+0% +$615 0.17% 62
2021
Q3 		$1.67M Sell
2,760
-585
-17% -$363K 0.19% 62
2021
Q2 		$1.95M Buy
+3,345
New +$1.69M 0.22% 58
2018
Q4 		– Sell
-33
Closed -$13K – 473
2018
Q3 		$13K Hold
33
– – ﹤0.01% 312
2018
Q2 		$11K Hold
33
– – ﹤0.01% 322
2018
Q1 		$11K Buy
+33
New +$11.5K 0.01% 319

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

McAdam LLC's REGN Position: Q1 2026 in Review

McAdam LLC sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 517 shares — an estimated $399K sold.

McAdam LLC first reported a position in REGN in Q1 2018 and held it in 19 quarters. The position peaked at $2.8M in Q2 2024. 1,399 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • McAdam LLC reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • McAdam LLC sold 517 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $399K.
  • McAdam LLC first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 19 quarters.
  • McAdam LLC's Regeneron Pharmaceuticals position peaked at $2.8M in Q2 2024.
  • 1,399 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on McAdam LLC's 13F filing for Q1 2026, filed 8 May 2026.